Nasivion

# nasivion ## Overview - **Classification**: Alpha-adrenergic agonist, topical decongestant. - **Mechanism**: Stimulates alpha-adrenergic receptors in nasal mucosa, causing vasoconstriction. This reduces blood flow and swelling, leading to nasal decongestion. ## Primary Indications 1. **Nasal Congestion** - Relief of stuffy nose due to common cold, sinusitis, or allergic rhinitis. 2. **Rhinitis** - Symptomatic relief in allergic or vasomotor rhinitis. 3. **Adjunct in Sinusitis** - Facilitates drainage of nasal and sinus secretions. ## Adult Dosing ### Standard Dosing **Nasal Congestion/Rhinitis** - **Dose**: **2-3 sprays** or **2-3 drops** of **0.05% solution** per nostril. - **Frequency**: Every **10-12 hours**. - **Route**: Intranasal. - **Duration**: Do not use for more than **3-5 days** to avoid rebound congestion. ### Dose Adjustments - **Renal Impairment**: No specific adjustments for topical use. - **Hepatic Impairment**: No specific adjustments for topical use. - **Elderly Patients**: Use with caution due to increased sensitivity; start with lowest effective dose. ## Pediatric Dosing *(Note: Use specific age-appropriate concentrations to avoid overdose)* ### Infants (0-1 year) - *Using **0.01% solution*** - **Dose**: **1 drop** of **0.01% solution** per nostril. - **Frequency**: **2-3 times daily**. - **Maximum**: Do not exceed **3 doses** in 24 hours. - **Special Notes**: Use only under medical supervision. High risk of systemic absorption. ### Children (1-6 years) - *Using **0.025% solution*** - **Dose**: **1-2 drops** of **0.025% solution** per nostril. - **Frequency**: **2-3 times daily**. - **Maximum**: Do not exceed **3 doses** in 24 hours. - **Special Notes**: Supervise administration. Limit duration to **3-5 days**. ### Children (6-12 years) - *Using **0.05% solution*** - **Dose**: **1-2 sprays** or **1-2 drops** of **0.05% solution** per nostril. - **Frequency**: Every **10-12 hours**. - **Maximum**: Do not exceed **2 doses** in 24 hours. - **Special Notes**: Limit duration to **3-5 days**. ### Adolescents (13-18 years) - **Dose**: Use **adult dosing** (**0.05% solution**). - **Maximum**: Adhere to adult maximum frequency and duration. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to oxymetazoline or excipients. - **Absolute**: Angle-closure glaucoma. - **Absolute**: Patients on MAO inhibitors (or within 14 days of stopping). - **Absolute**: Transsphenoidal hypophysectomy or surgery exposing dura mater. - **Relative**: Rhinitis sicca or atrophic rhinitis. ### Common Adverse Effects - **Common (1-10%)**: Stinging, burning, sneezing, dryness of nasal mucosa. - **Less Common**: Local irritation, headache, insomnia, palpitations, rebound congestion. - **Serious but Rare**: Systemic effects (hypertension, tachycardia), CNS depression (especially in children from overdose). ### Key Drug Interactions - **Monoamine Oxidase Inhibitors (MAOIs)**: Risk of hypertensive crisis; contraindicated. - **Tricyclic Antidepressants (TCAs)**: Potentiates pressor effects; use with caution. - **Beta-blockers**: Can potentially increase blood pressure; monitor BP. ## Monitoring & Follow-up - **Before Treatment**: Assess for contraindications (e.g., MAOI use, glaucoma). - **During Treatment**: Monitor for local irritation, signs of rebound congestion. - **Clinical Signs**: Watch for worsening symptoms, severe headache, palpitations, or if congestion persists >5 days. ## Clinical Pearls - 💡 **Tip 1**: Advise patients to limit use to **3-5 days** to prevent rebound congestion (rhinitis medicamentosa). - 💡 **Tip 2**: For pediatric use, ensure the **correct concentration** (0.01%, 0.025%, or 0.05%) is used for the appropriate age group. - 💡 **Tip 3**: Do not share nasal sprays to prevent germ transmission. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.